ABSTRACT
The mechanisms that regulate the T(H)9 subset of helper T cells and diseases mediated by T(H)9 cells remain poorly defined. Here we found that the costimulatory receptor OX40 was a powerful inducer of T(H)9 cells in vitro and T(H)9 cell-dependent airway inflammation in vivo. In polarizing conditions based on transforming growth factor-ß (TGF-ß), ligation of OX40 inhibited the production of induced regulatory T cells and the T(H)17 subset of helper T cells and diverted CD4(+)Foxp3(-) T cells to a T(H)9 phenotype. Mechanistically, OX40 activated the ubiquitin ligase TRAF6, which triggered induction of the kinase NIK in CD4(+) T cells and the noncanonical transcription factor NF-κB pathway; this subsequently led to the generation of T(H)9 cells. Thus, our study identifies a previously unknown mechanism for the induction of T(H)9 cells and may have important clinical implications in allergic inflammation.
Subject(s)
OX40 Ligand/metabolism , Receptors, OX40/metabolism , Respiratory System/immunology , T-Lymphocytes, Helper-Inducer/immunology , Animals , CD4 Antigens/biosynthesis , Humans , Inflammation/immunology , Inflammation/metabolism , Interleukin-9/biosynthesis , Interleukin-9/metabolism , Mice , NF-kappa B/metabolism , OX40 Ligand/immunology , Protein Serine-Threonine Kinases/biosynthesis , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins/immunology , Proto-Oncogene Proteins/metabolism , Receptors, OX40/immunology , Signal Transduction/immunology , T-Lymphocytes, Helper-Inducer/metabolism , TNF Receptor-Associated Factor 6/biosynthesis , TNF Receptor-Associated Factor 6/metabolism , Trans-Activators/immunology , Trans-Activators/metabolism , Transforming Growth Factor beta/immunology , Transforming Growth Factor beta/metabolism , NF-kappaB-Inducing KinaseABSTRACT
BACKGROUND: Tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) has been proved to play an important role in tumorigenesis, invasion, and metastasis. However, its precise role salivary adenoid cystic carcinoma (SACC) has not been determined. The aim of this study was to explore the role of TRAF6 in SACC including invasion and metastasis of SACC cells. MATERIALS AND METHODS: Immunohistochemistry and quantitative real-time PCR were performed in SACC tissues paired with their adjacent normal tissues to analyze the expression of TRAF6. Downstream proteins expression was explored when TRAF6 was knockdown by siRNA. RESULTS: The results show that TRAF6 is upregulated in SACC samples, especially in SACC with metastasis, which is closely correlated with an aggressive phenotype (P = .0073) and shorter life survival span (P = .0061) in SACC patients. Knockdown of TRAF6 can attenuate the promotion effect of SACC cell invasion induced by TGF-ß. Western blot results also showed that silencing TRAF6 expression can inhibit the activation of SMAD2, SMAD3, ERK, p38, and JNK induced by TGF-ß in SACC cells. CONCLUSION: These data suggested that TRAF6 regulates TGF-ß-mediated SACC progression through SMAD2/3-ERK-p38-JNK cascades.
Subject(s)
Carcinoma, Adenoid Cystic/metabolism , MAP Kinase Signaling System , Salivary Gland Neoplasms/metabolism , TNF Receptor-Associated Factor 6/metabolism , Transforming Growth Factor beta/pharmacology , Carcinogenesis , Carcinoma, Adenoid Cystic/genetics , Carcinoma, Adenoid Cystic/pathology , Cell Line, Tumor , Disease Progression , Female , Humans , Intracellular Signaling Peptides and Proteins , Male , Middle Aged , Neoplasm Invasiveness , Salivary Gland Neoplasms/genetics , Salivary Gland Neoplasms/pathology , Smad2 Protein/metabolism , Smad3 Protein/metabolism , TNF Receptor-Associated Factor 6/biosynthesis , TNF Receptor-Associated Factor 6/genetics , Transforming Growth Factor beta/metabolism , Up-Regulation , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
MicroRNAs have been shown to be important regulators of inflammatory and immune responses and are implicated in several immune disorders including systemic lupus erythematosus and rheumatoid arthritis, but their role in Lyme borreliosis remains unknown. We performed a microarray screen for expression of miRNAs in joint tissue from three mouse strains infected with Borrelia burgdorferi. This screen identified upregulation of miR-146a, a key negative regulator of NF-κB signaling, in all three strains, suggesting it plays an important role in the in vivo response to B. burgdorferi. Infection of B6 miR-146a-/- mice with B. burgdorferi revealed a critical nonredundant role of miR-146a in modulating Lyme arthritis without compromising host immune response or heart inflammation. The impact of miR-146a was specifically localized to the joint, and did not impact lesion development or inflammation in the heart. Furthermore, B6 miR-146a-/- mice had elevated levels of NF-κB-regulated products in joint tissue and serum late in infection. Flow cytometry analysis of various lineages isolated from infected joint tissue of mice showed that myeloid cell infiltration was significantly greater in B6 miR-146a-/- mice, compared to B6, during B. burgdorferi infection. Using bone marrow-derived macrophages, we found that TRAF6, a known target of miR-146a involved in NF-κB activation, was dysregulated in resting and B. burgdorferi-stimulated B6 miR-146a-/- macrophages, and corresponded to elevated IL-1ß, IL-6 and CXCL1 production. This dysregulated protein production was also observed in macrophages treated with IL-10 prior to B. burgdorferi stimulation. Peritoneal macrophages from B6 miR-146a-/- mice also showed enhanced phagocytosis of B. burgdorferi. Together, these data show that miR-146a-mediated regulation of TRAF6 and NF-κB, and downstream targets such as IL-1ß, IL-6 and CXCL1, are critical for modulation of Lyme arthritis during chronic infection with B. burgdorferi.
Subject(s)
Arthritis, Infectious/genetics , Borrelia burgdorferi/immunology , Lyme Disease/immunology , MicroRNAs/genetics , Myocarditis/genetics , Animals , Arthritis, Infectious/microbiology , Borrelia burgdorferi/pathogenicity , Chemokine CXCL1/immunology , Gene Expression Regulation/genetics , Inflammation/immunology , Inflammation Mediators/immunology , Interleukin-10/genetics , Interleukin-10/metabolism , Interleukin-1beta/immunology , Interleukin-6/immunology , Lyme Disease/genetics , Lyme Disease/pathology , Macrophages/immunology , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Knockout , Myocarditis/microbiology , NF-kappa B/genetics , NF-kappa B/immunology , Phagocytosis/genetics , Phagocytosis/immunology , Signal Transduction/immunology , TNF Receptor-Associated Factor 6/biosynthesis , TNF Receptor-Associated Factor 6/immunologyABSTRACT
Previously, we developed a novel microRNA (miRNA) delivery system based on bacteriophage MS2 virus-like particles (MS2 VLPs). In this current study, we used this system to transport miR-146a into human peripheral blood mononuclear cells (PBMCs), and demonstrated the inhibition of osteoclastogenesis in precursors. Two cytokines, receptor activator of NF-κB ligand (RANKL), and macrophage-colony stimulating factor (M-CSF) were used to induce osteoclastogenesis. MS2 VLPs were transfected into PBMCs. qRT-PCR was applied to measure expression levels of miR-146a and osteoclast (OC)-specific genes. Western blot (WB) was conducted to evaluate miR-146a downstream target proteins: epidermal growth factor receptor (EGFR) and tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6). The formation and activity of OCs were assessed by cytochemical staining and bone resorption assay, respectively. In PBMCs treated with MS2-miR146a VLPs, qRT-PCR assays showed increased expression of miR-146a (p < 0.01) and decreased expression of all four OC-specific genes (p < 0.05). WB results indicated decreased expression of EGFR (p < 0.01) and TRAF6 (p < 0.05). The number of OCs decreased markedly and bone resorption assay demonstrated inhibited activity. This miR-146a delivery system could be applied to induce overexpression of miR-146a and to inhibit the differentiation and function of OCs.
Subject(s)
MicroRNAs/genetics , Osteoclasts/physiology , Transfection , Animals , Cattle , Cell Differentiation , Cells, Cultured , ErbB Receptors/biosynthesis , ErbB Receptors/genetics , Gene Expression , Humans , Leukocytes, Mononuclear/physiology , TNF Receptor-Associated Factor 6/biosynthesis , TNF Receptor-Associated Factor 6/geneticsABSTRACT
Due to some severe side effects or lack of efficacy of currently used synthetic drugs, such as bisphosphonates (BPs), the search for new therapeutic agents that can more effectively prevent and treat osteoporosis (OP) has been an increasingly important topic of research. In this study, the low-molecular weight hyaluronan (LMW-HA, 50 kDa) produced by enzymatic degradation of high-molecular weight hyaluronan (HMW-HA, 1922 kDa) from Streptococcus zooepidemicus was evaluated in vitro for its anti-osteoclastogenic potentials using RAW 264.7 murine macrophage cells. LMW-HA (25-200 µg/ml) dose-dependently inhibited the receptor activator of NF-κB ligand (RANKL)-induced tartrate-resistance acid phosphatase (TRAP) activity and the formation of multinucleated osteoclasts. Western blot analysis showed that LMW-HA reduced the RANKL-induced expression of tumor necrosis factor receptor-associated factor 6 (TRAF6), gelsolin and c-Src-proline-rich tyrosine kinase 2 suggesting that it could inhibit actin ring formation of osteoclast cells. In addition, LMW-HA inhibited the bone resorption activity of osteoclastic cells by dose-dependently attenuating the RANKL-induced expression of carbonic anhydrase II and integrin ß3. RT-PCR analysis showed that LMW-HA dose-dependently decreased the expression of osteoclast-specific genes, such as matrix metalloproteinase 9 (MMP-9) and cathepsin K, suggesting that it has potential to inhibit the differentiation of osteoclastic cells. Taken collectively, these results suggested that LMW-HA (50 kDa) has significant anti-osteoporotic activity in vitro and may be used as a potent functional ingredient in health beneficial foods or as a therapeutic agent to prevent or treat OP.
Subject(s)
Hyaluronic Acid/pharmacology , Osteoporosis/drug therapy , Acid Phosphatase/metabolism , Animals , Cathepsin K/biosynthesis , Cell Differentiation/drug effects , Cell Line , Hyaluronic Acid/therapeutic use , Isoenzymes/metabolism , Macrophages/drug effects , Macrophages/metabolism , Matrix Metalloproteinase 9/biosynthesis , Mice , Molecular Weight , Osteoclasts/cytology , Osteoclasts/metabolism , RANK Ligand/antagonists & inhibitors , TNF Receptor-Associated Factor 6/biosynthesis , Tartrate-Resistant Acid PhosphataseABSTRACT
Tumor necrosis factor receptor-associated factor 6 (TRAF6) is a unique adaptor protein of the tumor necrosis factor receptor-associated factor family that mediates both tumor necrosis factor receptor and interleukin-1 receptor/Toll-like receptor signaling. A recent study showed that TRAF6 played an important role in tumorigenesis and invasion through activation of nuclear factor kappa B (NF-κB). However, the biological role of TRAF6 remains unknown in lung cancer up to now. To address the expression of TRAF6 in lung cancer cells, four lung cancer cell lines (A549, HCC827, NCI-H292, and 95-D) and human bronchial epithelial cells were used to detect the expression of TRAF6 protein by western blotting. Results indicated that TRAF6 displayed an upregulation in human lung cancer cell lines. To investigate the effects of TRAF6 on the biological behavior of human lung adenocarcinoma cell, we generated human lung adenocarcinoma A549 cell line in which TRAF6 was depleted. The results showed that downregulation of TRAF6 could decrease cell viability, suppress cell proliferation and invasion, and promote cell apoptosis. At the same time, we explored the effects of TRAF6 on the expression of the following proteins: phosphor-NF-κB (p-p65), cyclin D1, caspase-3, and matrix metalloproteinase 9 (MMP9). Downregulation of TRAF6 could decrease the expression of p-p65, cyclin D1, and MMP9 and increase the expression of caspase-3. All these results suggested that TRAF6 might be involved in the potentiation of growth, proliferation, and invasion of A549 cell line, as well as the inhibition of A549 cell apoptosis by the activation of NF-κB. To make a long story short, the overexpression of TRAF6 might be related to the tumorigenesis and invasion of lung cancer.
Subject(s)
Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , TNF Receptor-Associated Factor 6/metabolism , Adenocarcinoma/genetics , Apoptosis , Caspase 3/biosynthesis , Cell Line, Tumor , Cell Proliferation , Cell Survival , Cell Transformation, Neoplastic , Cyclin D1/biosynthesis , Down-Regulation , Humans , Lung Neoplasms/genetics , Matrix Metalloproteinase 9/biosynthesis , NF-kappa B/metabolism , Neoplasm Invasiveness , Signal Transduction , TNF Receptor-Associated Factor 6/biosynthesis , Transcription Factor RelA/biosynthesis , Up-RegulationABSTRACT
Tumor necrosis-associated factor 6 (TRAF6) performs critical roles in mediating apoptosis-associated inflammatory processes in multiple cell types, but its role in cerebral ischemia-reperfusion (I/R) injury is still unclear. In the present study, we established a middle cerebral artery occlusion (MCAO) reperfusion model in rat, and evaluated both the cerebral inflammatory damage and the cell apoptosis by TTC staining and TUNEL method, respectively. The expression of TRAF6 and the neural cell apoptosis was examined during the I/R pathophysiological process. Cerebral ischemia injury induced significant neuronal cell apoptosis, but after the onset of reperfusion, cell apoptosis was gradually alleviated. In accord with the trend of I/R injury and cell apoptosis, up-regulated TRAF6 mRNA expression and caspase-3 cleavage level were observed in the ischemia stage and the early stage of reperfusion accordingly, which indicated that the activation of TRAF6 correlated positively with the cell apoptosis. Immunohistochemistry staining further showed that the TRAF6 was mainly localized in the neuronal cells. Thus, our study suggested that TRAF6 is involved in the inflammatory process induced by cerebral ischemia-reperfusion, and functions partially as a pro-inflammatory adaptor to mediate cell apoptosis.
Subject(s)
Apoptosis/physiology , Brain Ischemia/metabolism , Reperfusion Injury/metabolism , TNF Receptor-Associated Factor 6/biosynthesis , Up-Regulation/physiology , Animals , Brain Ischemia/pathology , Male , Random Allocation , Rats , Rats, Sprague-Dawley , Reperfusion Injury/pathologyABSTRACT
To understand the biologic role of self-DNA bound to Toll-like Receptor 9 (TLR9), we assayed its effect on gene and methyltransferase expressions and cell differentiation in HT29 cells. HT29 cells were incubated separately with type-1 (normally methylated/nonfragmented), type-2 (normally methylated/fragmented), type-3 (hypermethylated/nonfragmented), or type-4 (hypermethylated/fragmented) self-DNAs. Expression levels of TLR9-signaling and proinflammatory cytokine-related genes were assayed by qRT-PCR. Methyltransferase activity and cell differentiation were examined by using DNA methyltransferase (DNMT1, -3A, -3B) and cytokeratin (CK) antibodies. Treatment with type-1 DNA resulted in significant increase in TLR9 expression. Type-2 treatment resulted in the overexpression of TLR9-related signaling molecules (MYD88A, TRAF6) and the IL8 gene. In the case of type-3 treatment, significant overexpression of NFkB, IRAK2, and IL8 as well as downregulation of TRAF6 was detected. Using type-4 DNA, TRAF6 and MYD88A gene expression was upregulated, while MYD88B, IRAK2, IL8, and TNFSF10 were all underexpressed. CK expression was significantly higher only after type-1 DNA treatment. DNMT3A expression could also be induced by type-1 DNA treatment. DNA structure may play a significant role in activation of the TLR9-dependent and even independent proinflammatory pathways. There may be a molecular link between TLR9 signaling and DNMT3A. The mode of self-DNA treatment may influence HT29 cell differentiation.
Subject(s)
DNA (Cytosine-5-)-Methyltransferases/metabolism , DNA Methylation/physiology , DNA/metabolism , Gene Expression Regulation/physiology , Keratins/biosynthesis , Toll-Like Receptor 9/metabolism , Cell Differentiation/physiology , Cell Line, Tumor , DNA/genetics , DNA (Cytosine-5-)-Methyltransferases/genetics , Humans , Interleukin-1 Receptor-Associated Kinases/biosynthesis , Interleukin-1 Receptor-Associated Kinases/genetics , Interleukin-8/genetics , Interleukin-8/metabolism , Myeloid Differentiation Factor 88/biosynthesis , Myeloid Differentiation Factor 88/genetics , NF-kappa B/genetics , NF-kappa B/metabolism , TNF Receptor-Associated Factor 6/biosynthesis , TNF Receptor-Associated Factor 6/genetics , TNF-Related Apoptosis-Inducing Ligand/genetics , TNF-Related Apoptosis-Inducing Ligand/metabolism , Toll-Like Receptor 9/agonists , Toll-Like Receptor 9/geneticsABSTRACT
Previous studies have reported that low molecular mass HA and highly polymerized HA respectively elicited pro- and anti-inflammatory responses by modulating the toll-like receptor 4 (TLR-4) and the TLR-2. The activation of TLR-4 and TLR-2 mediated by collagen-induced arthritis (CIA) induces the myeloid differentiation primary response protein (MyD88) and the tumor necrosis factor receptor-associated factor 6 (TRAF6), and ends with the liberation of NF-kB which, in turn, stimulates pro-inflammatory cytokine production. The aim of this study was to investigate the influence of high molecular weight HA at different concentrations on TLR-4 and TLR-2 modulation in CIA in mice. Arthritis was induced in mice via intradermal injection of an emulsion containing bovine type II collagen in complete Freund's adjuvant. Mice were treated with HA intraperitoneally daily for 30days. CIA increased TLR-4, TLR-2, MyD88 and TRAF6 mRNA expression and the related protein in the cartilage of arthritic joints. High levels of both mRNA and related protein were also detected for tumor necrosis factor alpha (TNF-α), interleukin 1-beta (IL-1-ß), interleukin-17 (IL-17), matrix metalloprotease-13 (MMP-13) and inducible nitric oxide synthase (iNOS) in the joint of arthritic mice. HA treatment significantly limited CIA incidence and decreased all the parameters up-regulated by CIA. The improvement of biochemical parameters was also supported by histological analysis, plasma and synovial fluid HA levels. These results suggest that the TLR-4 and TLR-2 play an important role in the arthritis mechanism and the interaction/block of HA at high molecular mass may reduce inflammation and cartilage injury.
Subject(s)
Arthritis, Experimental/pathology , Cartilage/metabolism , Hyaluronic Acid/pharmacology , Inflammation/pathology , Toll-Like Receptor 2/biosynthesis , Toll-Like Receptor 4/biosynthesis , Animals , Arthritis, Experimental/immunology , Cartilage/drug effects , Collagen Type II , Hyaluronic Acid/metabolism , Hyaluronic Acid/therapeutic use , Inflammation/immunology , Mice , Mice, Inbred DBA , Molecular Weight , Myeloid Differentiation Factor 88/biosynthesis , NF-kappa B/metabolism , Synovial Fluid/chemistry , TNF Receptor-Associated Factor 6/biosynthesisABSTRACT
Lipopolysaccharide (LPS) from Porphyromonas gingivalis, an oral Gram-negative bacterium, acts as a virulence factor for periodontal disease. Although P. gingivalis LPS does not induce proinflammatory cytokines as strongly as Escherichia coli LPS, it is still able to exploit negative Toll-like receptor (TLR) regulatory pathways and facilitate pathogen persistence. Recent reports suggest that microRNAs (miRNAs) are also involved in the regulation of TLR signaling. Here, we demonstrate that P. gingivalis LPS strongly induces miRNA-146a expression in THP-1 cells and THP-1-derived macrophages. However, the inhibition or overexpression of miR-146a, through the transfection of a specific inhibitor or precursor, respectively, had little effect on cytokine production in macrophages stimulated with P. gingivalis LPS. Moreover, the expression of interleukin-1 associated-kinase-1 (IRAK-1) and tumor-necrosis factor (TNF) receptor-associated factor-6 (TRAF6), potential target molecules of miR-146a, were not affected by the stimulation with P. gingivalis LPS. Because TLR signaling induces various negative regulators, these results call into question the role of miR-146a in cells stimulated with TLR ligands.
Subject(s)
Lipopolysaccharides/immunology , MicroRNAs/biosynthesis , Periodontitis/immunology , Periodontitis/microbiology , Porphyromonas gingivalis/immunology , Cell Line , Cytokines/biosynthesis , Humans , Interleukin-1 Receptor-Associated Kinases/biosynthesis , Interleukin-1 Receptor-Associated Kinases/genetics , Macrophages/immunology , Macrophages/microbiology , TNF Receptor-Associated Factor 6/biosynthesis , TNF Receptor-Associated Factor 6/genetics , Toll-Like Receptors/metabolismABSTRACT
Mechanical stress is known to be important for regulation of bone turnover, though the detailed mechanisms are not fully understood. In the present study, we examined the effect of mechanical stress on osteoblasts using a novel compression model. Mouse osteoblastic MC3T3-E1 cells were embedded in three-dimensional (3D) gels and cultured with continuous compressive force (0-10.0 g/cm(2)) for 48 h, and the conditioned medium were collected. RAW264.7 cells were then incubated with the conditioned medium for various times in the presence of receptor activator of nuclear factor-κB ligand (RANKL). Conditioned medium was found to inhibit the differentiation of RAW264.7 cells into osteoclasts induced by RANKL via down-regulation of the expression of tumor necrosis factor receptor-associated factor 6 (TRAF6), phosphorylation of IκBα, and nuclear translocation of p50 and p65. Interestingly, the conditioned medium also had a high level of binding activity to RANKL and blocked the binding of RANK to RANKL. Furthermore, the binding activity of conditioned medium to RANKL was reduced when the 3D gel was supplemented with KN-93, an inhibitor of non-canonical Wnt/Ca(2+) pathway. In addition, expression level of osteoprotegerin (OPG) mRNA was increased in time- and force-dependent manners, and remarkably suppressed by KN-93. These results indicate that osteoblastic cells subjected to mechanical stress produce OPG, which binds to RANKL. Furthermore, this binding activity strongly inhibited osteoclastogenesis through suppression of TRAF6 and the nuclear factor-kappa B (NF-κB) signaling pathway, suggesting that enhancement of OPG expression induced by mechanical stress is dependent on non-canonical Wnt/Ca(2+) pathway.
Subject(s)
Cell Differentiation , Mechanotransduction, Cellular , Osteoblasts/cytology , Osteoclasts/cytology , Stress, Mechanical , 3T3 Cells , Animals , Cell Differentiation/drug effects , Cell Line , Culture Media, Conditioned/pharmacology , Humans , Mice , NF-kappa B/metabolism , Osteoblasts/metabolism , Osteoblasts/physiology , Osteoclasts/metabolism , Osteoclasts/physiology , Osteoprotegerin/biosynthesis , RANK Ligand/pharmacology , TNF Receptor-Associated Factor 6/biosynthesisABSTRACT
Helicobacter pylori is a recognized cancerogenic bacterial agent in humans, associated with gastritis, peptic ulcer, and gastric cancer. Immunoevasive and immunomodulatory mechanisms underlie the chronic persistence of the bacterium and the active proinflammatory effect of life-long H. pylori infection. In contrast to tumorigenic viruses, which frequently possess factors to influence the host ubiquitin-proteasome system (UPS), nothing is yet known about potential effects of H. pylori in this respect. The majority of H. pylori isolates worldwide possess a pathogenicity island (PAI), the cagPAI, which is involved in IL-8 production and chronic inflammation. We hypothesized that H. pylori and its cagPAI may have an influence on host cell ubiquitin pathways. The effect of H. pylori wild type and isogenic mutants lacking the complete cagPAI (or CagA) on host deubiqutinating enzymes (DUBs) was tested in coincubation experiments with human gastric epithelial cells, using DUB activity profiling. Specific DUBs were identified to be active in gastric cells. Effects on the activity and expression of DUBs were observed in H. pylori-infected cells. In particular, H. pylori caused a strong decrease in the expression and activity of the DUB USP7 which was partially cagPAI- and CagA-dependent. The reduction in USP7 in infected cells at the protein and transcript levels coincided with a decrease in the amounts of the major innate immune hub protein TRAF6 and the tumor suppressor p53. These results are a basis for further investigations into H. pylori modulators of ubiquitin-dependent cellular signaling and their biological function.
Subject(s)
Helicobacter pylori/metabolism , Helicobacter pylori/pathogenicity , Host-Pathogen Interactions , TNF Receptor-Associated Factor 6/biosynthesis , Tumor Suppressor Protein p53/biosynthesis , Ubiquitin Thiolesterase/biosynthesis , Cells, Cultured , Coculture Techniques , Down-Regulation , Epithelial Cells/microbiology , Gene Expression , Gene Expression Profiling , Genomic Islands , Humans , Sequence Deletion , Ubiquitin-Specific Peptidase 7 , Virulence Factors/geneticsABSTRACT
IL-17 alone is a relatively weak inducer of gene expression, but cooperates with other cytokines, including TNF-alpha, to generate a strong response in part via prolongation of mRNA t(1/2). Because TNFR-associated factor 6 (TRAF6) has been reported to be essential for signaling by IL-17, we examined its involvement in IL-17-mediated mRNA stabilization. Although overexpression of TRAF6 in HeLa cells activates NF-kappaB, it does not stabilize transfected KC mRNA. Furthermore, a dominant-negative TRAF6 abrogates NF-kappaB activation, but does not block IL-17-induced chemokine mRNA stabilization. IL-17 can stabilize KC and MIP-2 mRNAs comparably in TNF-alpha-treated mouse embryo fibroblasts from TRAF6(+/+) and TRAF6(-/-) mice. TRAF6 is known to couple upstream signals with activation of p38 MAPK and mitogen activated protein kinase activated protein kinase 2, both of which have been shown to be important for Toll/IL-1R-mediated mRNA stabilization in various cell types. Inhibition of p38 MAPK, however, does not block IL-17-induced KC mRNA stabilization, and IL-17 can stabilize KC mRNA equally in mouse embryo fibroblasts from both wild-type and mitogen activated protein kinase activated protein kinase 2/3 doubly-deficient mice. Finally, IL-17 can amplify the levels of multiple TNF-alpha-stimulated mRNAs in wild-type and TRAF6-deficient cells, but not in cells from Act1(-/-) mice. Collectively, these findings demonstrate the existence of a TRAF6/p38 MAPK-independent pathway that couples the IL-17R with enhanced mRNA stability. Because the most potent effects of IL-17 on gene expression are obtained in cooperation with other cytokines such as TNF-alpha, these findings suggest that this pathway is a major contributing mechanism for response to IL-17.
Subject(s)
Interleukin-17/physiology , RNA Stability/immunology , RNA, Messenger/metabolism , Signal Transduction/immunology , TNF Receptor-Associated Factor 6/physiology , Animals , Cells, Cultured , Chemokines/biosynthesis , Chemokines/genetics , Gene Expression Regulation/immunology , HeLa Cells , Humans , Inflammation Mediators/physiology , Intracellular Signaling Peptides and Proteins/deficiency , Intracellular Signaling Peptides and Proteins/genetics , Intracellular Signaling Peptides and Proteins/physiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Protein Serine-Threonine Kinases/deficiency , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/physiology , RNA, Messenger/biosynthesis , Signal Transduction/genetics , TNF Receptor-Associated Factor 6/biosynthesis , TNF Receptor-Associated Factor 6/deficiency , TNF Receptor-Associated Factor 6/genetics , Tumor Necrosis Factor-alpha/physiology , p38 Mitogen-Activated Protein Kinases/physiologyABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Kaempferia rhizome is a famous traditional herbal medical in tropical and subtropical areas. Kaempferol (KPF) is one of the main bioactive compounds in Kaempferia rhizome, with anti-oxidant/anti-inflammatory effects demonstrated in various disease models, including cancers, obesity and diabetes. AIM OF THE STUDY: Inflammation plays an important role in the pathogenesis of diabetic nephropathy (DN). TRAF6 functions as a signal transducer in toll-like receptor 4 and NF-κB pro-inflammatory signaling pathway. We aimed at investigate whether KPF is able to mitigate inflammatory responses by regulating TRAF6 in DN. MATERIAL AND METHODS: C57BL/6 mice were injected with streptozotocin to induce type 1 DN. NRK-52E, a tubular epithelial cell line, was used for in vitro analysis. TRAF6 was knockdown using siRNA in vitro and AAV2/2-shRNA in vivo. The anti-DN and inflammatory effects of KPF or knockdown of TRAF6 were evaluated by investigating renal filtration index, pathological changes of kidney tissue. Proinflammatory cytokine levels were detected using ELISA. NF-κB pathway and protein levels of related pathways were detected through Western blot. RESULTS: KPF significantly reduced renal inflammation, fibrosis, and kidney dysfunction in diabetic mice. These effects were associated with a downregulation of TRAF6 in diabetic mouse kidneys, indicating the potential role of TRAF6. Knockdown of TRAF6 in mice through AAV2-shTRAF6 confirmed the importance of TRAF6 in DN. In vitro, treatment of KPF in NRK-52E cells attenuated high glucose (HG)-induced inflammatory and fibrogenic responses, associated with downregulated TRAF6 expression. The conclusion was further confirmed in NRK-52E cells by knocking down the expression and by overexpression of TRAF6. CONCLUSION: Our findings provide direct evidence that TRAF6 mediates diabetes-induced inflammation leading to renal dysfunction. We also show that KPF is a potential therapeutic agent to reduce inflammatory responses in DN. Also, TRAF6 may represent an interesting target to combat DN.
Subject(s)
Diabetic Nephropathies/drug therapy , Diabetic Nephropathies/metabolism , Down-Regulation/drug effects , Kaempferols/therapeutic use , TNF Receptor-Associated Factor 6/antagonists & inhibitors , Animals , Diabetic Nephropathies/chemically induced , Down-Regulation/physiology , HEK293 Cells , Humans , Kaempferols/pharmacology , Male , Mice , Mice, Inbred C57BL , Streptozocin , TNF Receptor-Associated Factor 6/biosynthesis , TNF Receptor-Associated Factor 6/geneticsABSTRACT
BACKGROUND: Obesity-induced chronic inflammation is a key component in the pathogenesis of insulin resistance and type-2 diabetes Objective: This study aimed to evaluate the effect of swimming exercise on pancreatic expression levels of inflammatory cytokines, miR-146a and NF-кB in type-2 diabetic male rats. METHODS: Twenty- eight male Wistar rats were divided into four groups: control (Con), exercise, diabetes and diabetic exercise (n = 7). Diabetes induction performed by the combination of high-fat diet (HFD, 4 weeks) and streptozotocin (35 mg/kg. ip). After induction of diabetes, the rats swam in the exercise groups for 12 weeks. Then, blood and tissue samples were collected. RESULTS: Our results indicated a significant increase in expression levels of miR-146, NF-κB and inflammatory cytokines (IL-6, TNF-α, and IL-1ß) while a significant decrease in pancreatic expression levels of TRAF6 and IRAK1 in diabetic group as compared to the control group. In contrast, swimming exercise resulted in a significant decrease in expression levels of miR-146a, NF-кB and inflammatory cytokines and a significant increase in expression levels of TRAF6 and IRAK1 in the exercise-diabetic group compared to the diabetic group. CONCLUSION: Our results indicated a significant increase in expression levels of miR-146, NF-κB and inflammatory cytokines (IL-6, TNF-α, and IL-1ß) while a significant decrease in pancreatic expression levels of TRAF6 and IRAK1 in diabetic group as compared to the control group. In contrast, swimming exercise resulted in a significant decrease in expression levels of miR-146a, NF-кB and inflammatory cytokines and a significant increase in expression levels of TRAF6 and IRAK1 in the exercise-diabetic group compared to the diabetic group.
Subject(s)
Cytokines/biosynthesis , Diabetes Mellitus, Type 2/metabolism , MicroRNAs/biosynthesis , NF-kappa B/biosynthesis , Pancreas/metabolism , Swimming/physiology , Animals , Diabetes Mellitus, Experimental/metabolism , Disease Models, Animal , Interleukin-1 Receptor-Associated Kinases/biosynthesis , Interleukin-1beta/biosynthesis , Interleukin-6/biosynthesis , Male , Rats , Rats, Wistar , TNF Receptor-Associated Factor 6/biosynthesis , Tumor Necrosis Factor-alpha/biosynthesisABSTRACT
The lncRNA nuclear enriched abundant transcript 1 (NEAT1) promotes sepsis-inflammatory responses and acute kidney injury (AKI), but little known about the underlying mechanisms. This study aims to investigate the roles of NEAT1 in regulating macrophage polarization and its potential for alleviating inflammatory responses during sepsis pathogenesis. Mouse RAW264.7 macrophages were treated with lipopolysaccharide (LPS) as a cellular inflammatory model. NEAT1 shRNA, miR-125a-5p mimics, and TRAF6-overexpressing vector were used to transfect RAW264.7 cells. NEAT1, miR-125a-5p, and mRNA levels of functional genes were detected by quantitative RT-PCR. Protein abundances were analyzed by western blotting. Macrophage polarization was evaluated by flow cytometry. The bindings of miR-125a-5p with NEAT1 or TRAF6 gene were validated by dual luciferase reporter assay. LPS treatment promoted NEAT1 and suppressed miR-125a-5p expression in mouse macrophage cells. NEAT1 silencing by shRNAs promoted macrophage M2 polarization under LPS treatment, which upregulated miR-125a-5p expression, repressed TRAF6 expression and TAK1 protein phosphorylation in macrophages. These cellular and molecular changes induced by NEAT1 shRNAs were abrogated by miR-125a-5p inhibitors. Moreover, miR-125a-5p mimics suppressed TRAF6 expression and TAK1 protein phosphorylation in LPS-treated macrophages, thus causing macrophage M2 polarization under LPS treatment. TRAF6 overexpression abrogated the miR-125a-5p mimics-induced macrophage M2 polarization. miR-125a-5p could directly bind to NEAT1 or TRAF6 gene in macrophages. lncRNA NEAT1 knockdown ameliorates LPS-induced inflammation by promoting macrophage M2 polarization via miR-125a-5p/TRAF6/TAK1 axis.
Subject(s)
Cell Polarity/physiology , MAP Kinase Kinase Kinases/biosynthesis , Macrophages/metabolism , MicroRNAs/biosynthesis , RNA, Long Noncoding/biosynthesis , TNF Receptor-Associated Factor 6/biosynthesis , Animals , Cell Polarity/drug effects , Down-Regulation/drug effects , Down-Regulation/physiology , HEK293 Cells , Humans , Inflammation/chemically induced , Inflammation/metabolism , Inflammation/prevention & control , Lipopolysaccharides/toxicity , Macrophages/drug effects , Mice , RAW 264.7 Cells , RNA, Long Noncoding/antagonists & inhibitorsABSTRACT
OBJECTIVE: To explore the effect of miRNA-143 on osteoclast formation and provide new ideas for the treatment of osteoporosis. METHODS: Mice macrophage lines RAW264.7 cells after transfection were divided into four groups: control group, RANKL group, RANKL combined with miR-143 mimics group and RANKL combined with miR-NC group. TARCP staining was used to observe the effect of miR-143 on osteoclast formation. The expression of RANK, TRAF6 and NFATc-1 in the upstream of RANKL pathway was detected by real-time quantitative PCR (RT qPCR) and Western blotting (WB). The binding of miR-143 to TNFRSF11A was detected by double Luciferase Reporter Analysis. The effect of miR-143 on the expression of NF-κB (p65, I-κB-α) signal pathway in osteoclasts was detected. The effects of I-BET151 on the expression of osteoclast-specific genes TRACP, MMP 9, CtsK and c-Src were detected. RESULTS: The positive level of osteoclasts in RANKL group and RANKL combined with miR-NC group was significantly higher than that of RANKL combined with miR-143 mimics group and control group (P < 0.05). The expression levels of RANK, TRAF6, NFATc-1, TRACP, MMP-9, CtsK and c-Src in RANKL group and RANKL combined with miR-NC group were significantly higher than those of RANKL combined with miR-143 mimics group and control group (P < 0.05). The expression levels of I-κB-α were significantly lower than that of RANKL combined with miR-143 mimics group and control group (P<0.05). CONCLUSION: MiR-143 can inhibit the expression of RANK, TRAF6 and downstream NFATc-1 in the RANKL pathway, thereby inhibiting the RANK/RANKL pathway. MiR-143 can inhibit the signal pathway of NF-κB (p65, I-κB-α). MiR-143 inhibits the expression of osteoclast-specific genes TRACP, MMP 9, CtsK and c-Src. That is to say, miR-143 inhibits osteoclast formation by targeting RANK, NF- κB and MAPK signaling pathways.
Subject(s)
MicroRNAs/genetics , Osteoclasts/drug effects , Receptor Activator of Nuclear Factor-kappa B/antagonists & inhibitors , Signal Transduction/drug effects , Animals , Gene Expression Regulation/drug effects , MAP Kinase Signaling System/drug effects , Mice , NF-KappaB Inhibitor alpha/biosynthesis , NF-KappaB Inhibitor alpha/genetics , NFATC Transcription Factors/biosynthesis , NFATC Transcription Factors/genetics , Osteoclasts/metabolism , RANK Ligand/genetics , RAW 264.7 Cells , RNA, Messenger/biosynthesis , Receptor Activator of Nuclear Factor-kappa B/biosynthesis , Receptor Activator of Nuclear Factor-kappa B/genetics , Recombinant Proteins/metabolism , TNF Receptor-Associated Factor 6/biosynthesis , TNF Receptor-Associated Factor 6/genetics , Transcription Factor RelA/biosynthesis , Transcription Factor RelA/geneticsABSTRACT
Aberrant expression of tumor necrosis factor receptor-associated factor 6 (TRAF6) was reported in several types of cancers and it was demonstrated to promote tumor progression. In glioblastoma multiforme (GBM), TRAF6 depression by miRNA could decrease GBM cell resistance to temozolomide, but the prognostic values of TRAF6 and its functions in GBM progression have not been elucidated. In our study, the expression of TRAF6 and matrix metalloprotein 9 (MMP9) in 101 cases of GBM were investigated using immunohistochemistry. Twelve pairs of GBM frozen tissues and their corresponding adjacent tissues were collected during operation prospectively, and TRAF6 and MMP9 mRNA levels in them were detected using qRT-PCR. The correlations between TRAF6, MMP9, and clinicopathological factors were analyzed using the Chi-square test, and the prognostic value of TRAF6 and MMP9 were evaluated using univariate and multivariate analysis. The effect of TRAF6 and MMP9 on GBM cell invasion and proliferation was detected with experiments in vitro, and the correlation between TRAF6 and MMP9 expression was explored by regulating their expression with overexpression or knockdown. The expression of TRAF6 and MMP9 in GBM tissues was significantly higher than that in adjacent tissues. The expression of TRAF6 and MMP9 was significantly associated in GBM tissues. Both TRAF6 and MMP9 correlated with poor prognosis of GBM, and TRAF6 was identified as an independent prognostic factor of GBM. TRAF6 could promote invasion instead of proliferation of GBM cells via elevating expression of MMP9. TRAF6 was identified as an independent prognostic factor of GBM, with ability to promote invasion of GBM cells via elevating expression of MMP9.
Subject(s)
Biomarkers, Tumor/biosynthesis , Brain Neoplasms/metabolism , Glioblastoma/metabolism , Matrix Metalloproteinase 9/biosynthesis , TNF Receptor-Associated Factor 6/biosynthesis , Adult , Biomarkers, Tumor/genetics , Brain Neoplasms/diagnosis , Brain Neoplasms/genetics , Cell Line, Tumor , Female , Gene Expression Regulation, Neoplastic , Glioblastoma/diagnosis , Glioblastoma/genetics , Humans , Intracellular Signaling Peptides and Proteins , Male , Matrix Metalloproteinase 9/genetics , Middle Aged , Neoplasm Invasiveness/genetics , Neoplasm Invasiveness/pathology , Prognosis , Single-Blind Method , TNF Receptor-Associated Factor 6/geneticsABSTRACT
Recent evidence suggests that lipopolysaccharide (LPS) endotoxaemia in a rat causes significant mucosal injury. Our objective was to determine the effects of glutamine (Gln) on Toll-like receptor 4 (TLR-4), myeloid differentiation factor 88 (Myd88) and tumour necrosis factor (TNF)-alpha receptor-associated factor 6 (TRAF6) expression in intestinal mucosa following LPS endotoxaemia in a rat. For this purpose, male Sprague-Dawley rats were assigned randomly to one of three experimental groups of 10 rats each: (i) control rats underwent intraperitoneal (i.p.) injection of sterile saline once a day; (ii) rats were treated with LPS given i.p. once a day at a dose of 10 mg/kg for 48 h (two doses); and (iii) rats were pretreated with oral Gln given in drinking water (2%) 48 h before and following injection of LPS. Intestinal mucosal parameters, enterocyte proliferation and apoptosis were determined at death. TLR-4 and MyD88 mRNA expression was measured with reverse transcription-polymerase chain reaction (RT-PCR). TLR-4 and MyD88 protein expression were analysed by Western immunoblotting. We observed a statistically significant (P < 0.05) decrease in mucosal weight, mucosal DNA and enterocyte proliferation and a significant increase in enterocyte apoptosis in rat intestine, following LPS administration. These changes were attenuated significantly by dietary Gln. Expression of TLR-4, MyD88 and TRAF6 mRNA in the mucosal ileum was significantly higher in LPS rats versus control rats (P = 0.0006, P = 0.0015, P = 0.03, respectively) as well as TLR-4 and MyD88 protein expression. The administration of Gln reduced significantly the expression of TLR-4, MyD88 and TRAF6 (P = 0.023, P = 0.014, P = 0.035, respectively) mRNA as well as TLR-4 and MyD88 protein expression in ileum compared to LPS animals. We did not find a significant change in the expression of TLR-4, MyD88 or TRAF6 in the jejunum of different groups. We conclude that treatment with Gln was associated with down-regulation of TLR-4, MyD88 and TRAF6 expression and concomitant decrease in intestinal mucosal injury caused by LPS endotoxaemia in a rat.
Subject(s)
Down-Regulation/drug effects , Endotoxemia/immunology , Glutamine/pharmacology , Myeloid Differentiation Factor 88/biosynthesis , Toll-Like Receptor 4/biosynthesis , Animals , Apoptosis/drug effects , Apoptosis/immunology , Cell Proliferation/drug effects , Endotoxemia/drug therapy , Endotoxemia/pathology , Glutamine/therapeutic use , Intestinal Mucosa/immunology , Intestinal Mucosa/pathology , Intestine, Small/immunology , Intestine, Small/pathology , Lipopolysaccharides/toxicity , Male , Myeloid Differentiation Factor 88/genetics , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , TNF Receptor-Associated Factor 6/biosynthesis , TNF Receptor-Associated Factor 6/genetics , Toll-Like Receptor 4/geneticsABSTRACT
BACKGROUND: MicroRNAs (miRNAs) serve as important regulators of inflammatory and immune responses and are implicated in several immune disorders including gouty arthritis. The expression of miR-146a is upregulated in the peripheral blood mononuclear cells of patients with inter-critical gout when compared to normouricemic and hyperuricemic controls and those patients with acute gout flares. However, the role of miR-146a in the development of gout remains unknown. Here, we used miR-146a knockout (KO) mice to test miR-146a function in a monosodium urate (MSU)-induced gouty arthritis model. METHODS: The footpad or ankle joint of miR-146a KO and wild-type (WT) mice were injected with an MSU suspension to induce acute gouty arthritis. Bone marrow-derived macrophages (BMDMs) were stimulated with MSU and the gene expression of miR-146a; interleukin 1 beta (IL-1ß); tumor necrosis factor-α (TNF-α); and the NACHT, LRR and PYD domains-containing protein 3 (NALP3) inflammasome was evaluated. TNF-α and IL-1ß protein levels in BMDMs were assessed by fluorescence-activated cell sorting and western blot analyses. Gene and protein levels of TNF receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase (IRAK1), the targets of miR-146a, were also measured. RESULTS: Significantly increased paw swelling and index and ankle joint swelling were observed in miR-146a KO mice compared to WT controls after MSU treatment. MiR-146a expression in BMDMs from WT mice was dramatically upregulated at 4 h following MSU stimulation. Additionally, the expression of IL-1ß, TNF-α, and NALP3 was higher in BMDMs from miR-146a KO mice after exposure to MSU crystals compared to those from WT mice. Consistent with the observed gene expression, the IL-1ß and TNF-α proteins were upregulated in miR-146a KO mice. Additionally quantitative RT-PCR and western blot demonstrated that TRAF6 and IRAK1 were dramatically upregulated in BMDMs from miR-146 KO mice compared to those from WT mice. CONCLUSIONS: Collectively, these observations suggest that miR-146a provides negative feedback regulation of gouty arthritis development and lack of miR-146a enhances gouty arthritis via upregulation of TRAK6, IRAK-1, and the NALP3 inflammasome function.